Postoperative Pain
Conditions
Brief summary
The purpose of this study is to investigate the analgesic effect of low-dose intravenous ketamine in pregnant mothers undergoing cesarean section under Bupivacaine spinal anesthesia.
Detailed description
* No premedication will be given, and patients will be monitored by electrocardiogram, non-invasive arterial blood pressure, and pulse oximetry when they entered the operating room. * 18 gauge IV cannula will be inserted and all patients will be preloaded with 10 ml/kg of lactate ringer over 20 min period. * All participants will have spinal anesthesia using bupivacaine. The dose of the drug, as well as the method of injection will be identical for all individuals; 10 mg (2 cc 0.5%), in the L4-L5 space using needle 25 G, midline, with the patient in a sitting position. * After administering bupivacaine, and prior to surgery the height of the sensory block will be assessed bilaterally (complete loss of sensation to ice) in a ascending fashion starting from T12 dermatome. * Once adequate anesthesia to at least T6 dermatome will be achieved, the operation will be allowed to begin. When systolic blood pressure decrease to \< 90 mmHg, or 30% of the pre-anesthetic blood pressure, it will be corrected by administering 5 mg ephedrine. * Patients will be asked to report any intraoperative pain using visual pain score(VPS)of 0(no pain) 10(worst pain).
Interventions
DRUGKetamine
will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
OTHERNormal saline
will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Eligible women ASA class 1 and 2, are at term (≥37 week gestation), Scheduled for elective cesarean section whose anesthetic plan is for spinal anesthesia with Bupivacaine and intravenous pethidine and paracetamol for post operative analgesia.
Exclusion criteria
* • Body mass index ≥40 kg/m2, * Known allergy to any of the study medications, * Contraindication to the spinal anesthesia, * History of substance abuse, * History of hallucinations, * Chronic opioid therapy, * Chronic pain.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Number of Subjects Requiring Supplemental Analgesia | 24 hours postoperative |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative morphine/paracetamol | 24 hours postoperative |
| Number of subjects reporting nausea, vomiting | 24 hours postoperative |
Countries
Egypt
Contacts
Primary ContactAbdelrady S Ibrahim, MD
Backup ContactHamdy A Yousef, MD
Outcome results
None listed